Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3047% below fair value
$1.32−0.04 (-2.94%)
Close on Nov 16, 2026Market cap $6.07MP/E –Yield –
Biomerica EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Biomerica's EPS for the twelve months ending Aug 31, 2026 was -$1.63. For fiscal 2026 it was -$1.30. The highest annual figure on record is $0.64 in fiscal 2012.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | -$1.30 | – |
| FY2025 | May 31, 2025 | -$2.16 | – |
| FY2024 | May 31, 2024 | -$2.84 | – |
| FY2023 | May 31, 2023 | -$4.00 | – |
| FY2022 | May 31, 2022 | -$2.88 | – |
| FY2021 | May 31, 2021 | -$4.96 | – |
| FY2020 | May 31, 2020 | -$2.08 | – |
| FY2019 | May 31, 2019 | -$2.08 | – |
| FY2018 | May 31, 2018 | -$1.36 | – |
| FY2017 | May 31, 2017 | -$0.88 | – |
| FY2016 | May 31, 2016 | -$1.60 | – |
| FY2015 | May 31, 2015 | -$0.32 | – |
| FY2014 | May 31, 2014 | -$0.24 | -142.9% |
| FY2013 | May 31, 2013 | $0.56 | -12.5% |
| FY2012 | May 31, 2012 | $0.64 | +300.0% |
| FY2011 | May 31, 2011 | $0.16 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -$0.37 | – |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -$0.37 | – |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -$0.44 | – |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -$0.45 | – |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $0.00 | – |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -$0.70 | – |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -$0.48 | – |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -$0.06 | – |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -$0.63 | – |
| Q4 FY2024CQ2 2024 | May 31, 2024 | -$0.68 | – |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$0.88 | – |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -$0.72 | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | -$0.56 | – |
| Q4 FY2023CQ2 2023 | May 31, 2023 | -$0.86 | – |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | -$0.96 | – |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$0.96 | – |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -$1.28 | – |
| Q4 FY2022CQ2 2022 | May 31, 2022 | -$1.09 | – |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | -$0.08 | – |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | -$0.72 | – |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | -$0.96 | – |
| Q4 FY2021CQ2 2021 | May 31, 2021 | -$1.11 | – |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -$1.44 | – |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | -$1.20 | – |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | -$1.28 | – |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -$0.60 | – |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | -$0.72 | – |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | -$0.40 | – |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | -$0.40 | – |
| Q4 FY2019CQ2 2019 | May 31, 2019 | -$0.66 | – |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | -$0.56 | – |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | -$0.40 | – |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | -$0.40 | – |
| Q4 FY2018CQ2 2018 | May 31, 2018 | -$0.61 | – |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | -$0.32 | – |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | -$0.24 | – |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | -$0.16 | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | -$0.33 | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | -$0.32 | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | -$0.16 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?